An interventional study of Low-dose chest CT scan in Smoking, sponsored by Hospital St. Joseph, Marseille, France. Recruiting at 1 site in France. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-12-06.
Sponsored by Hospital St. Joseph, Marseille, France · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Smoking with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Smoking · France.
Among the 36 studies in Smoking with a site in France, this one is the 2nd largest by planned enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2022, is one of 19 with no phase, and was the 30th registered.
1,510 studies on the registry are indexed under Smoking; 193 are open to participants now.
Browse Smoking studies →7 of the 36 studies in Smoking with a site in France are open now. Recruiting first, the newest first:
Clinique de la Mitterie · Sites in France
Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 140 Smoking studies recruiting now, 74 (53%) set no upper age limit and 48 (34%) stop at 75 or younger; 3 take children under 18; 65 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 3 · Phase 4 4
First in 2005; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 1,000 is above the median of 115 across 1,165 interventional studies indexed under Smoking.
Median enrollment 135 across the 29 interventional studies, 195 across the 7 observational. Of the 24 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 36 have an industry lead sponsor. The 10 most frequent:
Hospital St. Joseph, Marseille, France is the lead sponsor of 31 studies on the registry; 4 are open to participants now.
Hospital St. Joseph, Marseille, France has 1 study filed under Smoking — fewer than ten, so there is no comparison to draw.
3 of the studies in Smoking with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06910566Centre Oscar LambretFactors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy | 2026-11 |
| NCT06500117Centre Hospitalier Universitaire DijonDigital Mindfulness Training Programme for Smoking Cessation and Maintenance | 2027-10 |
| NCT07907601Centre Hospitalier Universitaire de NīmesImpact of Multidisciplinary Care, Structured and Targeted on the COPD Patient's Clinical Pathway. | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Smoking with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diagnostic performance of low-dose chest CT scan combined with lung-RADS classification (version 1.1) for lung cancer screening among former and current smokers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: Low-dose chest CT scan
baseline, 1-year, 3-year and 5-year low-dose CT scan
Positive Predictive Value (PPV)
Time frame: 5 years
Sensitivity
Time frame: 5 years
Specificity
Time frame: 5 years
Early stage lung cancer detection rate (stage I and II)
Time frame: 5 years
5-year survival rate of patients who have undergone thoracic surgery
Time frame: 5 years
Rate of smoking-related co-morbidities detected on low-dose CT scan
smoking-related co-morbities = pulmonary emphysema, interstitial lung disease, atheromatous disease, hepatic steatosis and ascending aortic aneurysm.
Time frame: 5 years
Rate of additional examinations (including invasive diagnostic tests and surgery with benign results)
Time frame: 5 years
Risk ratio of lung cancer
Time frame: 5 years
Number of false positive results
Time frame: 5 years
Penetration rate
number of subjects included / number of includible subjects
Time frame: 5 years
Smoking cessation rates
Time frame: 5 years
EORTC QLQ-C30 score (version 3)
The EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions. The EORTC QLQ-C30 is composed of 9 multi-item scales: 5 functioning scales (physical, role, cognitive, emotional and social), a global QOL scale, and 3 symptom scales (fatigue, pain and nausea/vomiting). In addition, several single item symptom measures are used. For the five functioning scales and the global quality of life scale, a higher score represents a better level of functioning. For the symptom scales and items, a high score corresponds to a higher level of symptomatology.
Time frame: 5 years
Started Nov 2022 (actual). Primary completion is estimated for Oct 2028, 71 months after the start.
Of 402 non-industry interventional studies with no phase under Smoking, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 71 months is above that.
Counting every sponsor, half of 457 studies reached it within 23 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital St. Joseph, Marseille, France